Table 2.
Predictors of progression-free survival and overall survival after matching
| Univariable analysis | Multivariable analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| PFS analyses | ||||||
| ECOG PS (1 vs. 0) | 1.10 | 0.85–1.41 | 0.466 | |||
| Etiology (HBV vs. others) | 0.92 | 0.72–1.18 | 0.532 | |||
| Cirrhosis (present vs. absent) | 1.05 | 0.81–1.36 | 0.706 | |||
| Child-Pugh class (B vs. A) | 1.27 | 0.94–1.72 | 0.123 | |||
| BCLC stage (C vs. B) | 1.75 | 1.37–2.23 | <0.001 | 1.50 | 0.96–2.34 | 0.073 |
| Up-to-seven criteria (>7 vs. ≤7) | 1.42 | 1.09–1.86 | 0.010 | 1.27 | 0.95–1.69 | 0.103 |
| Macroscopic portal vein invasion (present vs. absent) | 1.47 | 1.17–1.85 | 0.001 | 1.01 | 0.71–1.45 | 0.939 |
| Extrahepatic spread (present vs. absent) | 1.46 | 1.15–1.85 | 0.002 | 1.16 | 0.84–1.61 | 0.360 |
| TACE type (DEB-TACE vs. cTACE) | 1.06 | 0.82–1.36 | 0.677 | |||
| HCC-related treatment history (present vs. absent) | 0.63 | 0.49–0.81 | <0.001 | 0.76 | 0.48–1.19 | 0.224 |
| Previous TACE history (present vs. absent) | 0.66 | 0.50–0.87 | 0.004 | 0.95 | 0.59–1.54 | 0.837 |
| Treatment (combination therapy vs. monotherapy) | 0.76 | 0.60–0.95 | 0.016 | 0.70 | 0.56–0.88 | 0.002 |
| OS analyses | ||||||
| ECOG PS (1 vs. 0) | 1.12 | 0.83–1.52 | 0.461 | |||
| Etiology (HBV vs. others) | 0.87 | 0.64–1.17 | 0.345 | |||
| Cirrhosis (present vs. absent) | 1.05 | 0.76–1.44 | 0.765 | |||
| Child-Pugh class (B vs. A) | 1.56 | 1.10–2.21 | 0.013 | 1.21 | 0.84–1.74 | 0.307 |
| BCLC stage (C vs. B) | 1.84 | 1.36–2.49 | <0.001 | 1.14 | 0.66–1.98 | 0.631 |
| Up-to-seven criteria (>7 vs. ≤7) | 1.81 | 1.27–2.59 | 0.001 | 1.49 | 1.03–2.17 | 0.034 |
| Macroscopic portal vein invasion (present vs. absent) | 1.75 | 1.33–2.31 | <0.001 | 1.32 | 0.84–2.05 | 0.225 |
| Extrahepatic spread (present vs. absent) | 1.49 | 1.12–1.98 | 0.007 | 1.29 | 0.88–1.89 | 0.200 |
| TACE type (DEB-TACE vs. cTACE) | 1.08 | 0.79–1.49 | 0.621 | |||
| HCC-related treatment history (present vs. absent) | 0.46 | 0.34–0.63 | <0.001 | 0.54 | 0.30–0.96 | 0.037 |
| Previous TACE history (present vs. absent) | 0.54 | 0.38–0.77 | 0.001 | 1.05 | 0.56–1.96 | 0.881 |
| Treatment (combination therapy vs. monotherapy) | 0.75 | 0.57–0.98 | 0.037 | 0.63 | 0.47–0.83 | 0.001 |
The multivariable analysis includes the variables with P-value ≤0.1 from the univariable analysis
HR hazard ratio, CI confidence intervals, ECOG PS Eastern Cooperative Oncology Group performance status, HBV hepatitis B virus, BCLC Barcelona Clinic Liver Cancer, TACE transarterial chemoembolization, cTACE conventional TACE, DEB-TACE drug-eluting beads TACE, HCC hepatocellular carcinoma